Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT02060565
Recruiting Observational

Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease

NCT02060565 · tracked via the Priya Life Science France tracker
Sponsor
Association HGE CHU Bordeaux Sud
Phase
Observational
Started
2014-02
Last updated
2023-07-20

Condition(s) studied

Chronic Liver Disease

Study summary

The aim of this retrospective and prospective study is to evaluate the 20-year prognosis value of non-invasive methods for the diagnosis of chronic liver disease for predicting survival and complications of cirrhosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * chronic hepatitis C * chronic hepatitis B * alcohol liver disease * non alcoholic liver disease Exclusion Criteria: * ascitis

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre d'Investigation de la Fibrose hépatique Service Hépato-Gastroentérologie Hopital Haut-Lévèque Pessac France Recruiting

Other trials for the same condition

VIATORR Device Registry Active, not recruiting
Albumin Modifications as Early Biomarkers of Chronic Liver Diseases Recruiting
FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02060565 on ClinicalTrials.gov ↗ ← All trials in France